95% of researchers rate our articles as excellent or good
Learn more about the work of our research integrity team to safeguard the quality of each article we publish.
Find out more
ORIGINAL RESEARCH article
Front. Med.
Sec. Pulmonary Medicine
Volume 12 - 2025 | doi: 10.3389/fmed.2025.1565098
Dexmedetomidine Administration Reduced Mortality in Patients with Acute Respiratory Distress Syndrome: A Propensity Score-Matched Cohort Analysis
Provisionally accepted- 1 Department of Critical Care Medicine, the First Affiliated Hospital of Gannan Medical University, Ganzhou, Jiangxi, China., Ganzhou, China
- 2 The first Clinical Medical College of Gannan Medical University, Ganzhou, Jiangxi Province, China
Background: Acute respiratory distress syndrome (ARDS) continues to pose significant difficulties due to the scarcity of successful preventative and therapeutic measures. Recent clinical trials and experimental research have confirmed the lungprotective and anti-inflammatory properties of dexmedetomidine. The objective of this study was to examine the relationship between the use of dexmedetomidine and mortality outcomes in ICU patients with ARDS.Methods: This study retrospectively examined data from the Medical Information Mart for Intensive Care (MIMIC) IV, focusing on individuals diagnosed with ARDS. The primary endpoint was the occurrence of death within 28 days after entering the ICU. To ensure a balanced cohort, we applied propensity score matching at a 1:1 ratio.Additionally, multivariable analysis was performed to mitigate the effects of confounding factors.In this study, a cohort comprising 612 patients diagnosed with ARDS was investigated. Analysis using both univariate and multivariate Cox regression indicated significantly reduced 28-day and 90-day mortality rates in patients administered dexmedetomidine compared to those who were not given this treatment. Following adjustments for potential confounders using propensity score matching, these results were confirmed to be robust.The results indicate an association between the administration of dexmedetomidine and lower mortality rates among severely ill ARDS patients.However, this result should be interpreted with cause because of a lot of missing data 2 of potential risk factors for clinical outcomes. Nonetheless, it is imperative to perform further randomized controlled trials to corroborate this finding.
Keywords: Dexmedetomidine, Acute Respiratory Distress Syndrome, Retrospective cohort study, Mortality, Propensity Score, MIMIC IV database
Received: 22 Jan 2025; Accepted: 07 Apr 2025.
Copyright: © 2025 Ye, Yu and Liu. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence:
Conglin Ye, Department of Critical Care Medicine, the First Affiliated Hospital of Gannan Medical University, Ganzhou, Jiangxi, China., Ganzhou, China
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.